Attached files
| file | filename |
|---|---|
| EX-10.1 - Travere Therapeutics, Inc. | e611162_ex10-1.htm |
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
|
|||
|
FORM 8-K
|
|||
|
CURRENT REPORT
|
|||
|
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
|
|||
|
Date of Report (Date of earliest event reported) June 30, 2013
|
|||
|
RETROPHIN, INC.
|
|||
|
(Exact name of registrant as specified in its charter)
|
|||
|
Delaware
|
000-53293
|
26-2383102
|
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
|
|
777 Third Avenue, Suite 22, New York, NY
|
10017
|
||
|
(Address of principal executive offices)
|
(Zip Code)
|
||
|
Registrant’s telephone number, including area code (212) 983-1310
|
|||
|
|
|||
|
(Former name or former address, if changed since last report.)
|
|||
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|||
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
||
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
||
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
||
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))
|
||
|
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
As of June 30, 2013, Retrophin, Inc. (the “Company”) and Marc Panoff entered into an amendment (the “Amendment”) to the Employment Agreement, dated as of May 7, 2013, pursuant to which the initial vesting of a pro rata portion of the restricted common stock granted under the Employment Agreement was changed from June 30, 2013 to December 31, 2013. All other terms of the Employment Agreement remain in full force and effect.
The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
Exhibits:
|
10.1
|
Amendment to Employment Agreement, dated as of June 30, 2013.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
RETROPHIN, INC.
|
|||
|
Date: July 29 , 2013
|
By:
|
/s/ Martin Shkreli | |
|
Name: Martin Shkreli
|
|||
|
Title: Chief Executive Officer
|
|||